A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (CCS1477-04)
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Not open
Phase: II
Principal Investigator: Holstein, Sarah
Contact Information:
Marnee Strege
+1 402-559-8155
marnee.strege@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07096778?term=NCT07096778&rank=1#participation-criteria
Summary
Primary: -To assess the efficacy of InoPd Secondary: -To further assess the efficacy of InoPd-To assess the safety and tolerability of InoPd Exploratory:-To assess the presence of MRD-To assess the PK and pharmacodynamics of inobrodib when administered in combination with pomalidomide and dexamethasone-To assess the impact of InoPd on HRQoL-To collect and assess healthcare resource use data